Pioglitazone reduces monocyte activation in type 2 diabetes

Acta Diabetologica

Volumn 46, Issue 1, 2009, Pages 75-77

  Pitocco, Dario ^a   Giubilato, Simona ^a   Zaccardi, Francesco ^a   Di Stasio, Enrico ^a   Buffon, Antonino ^a   Biasucci, Luigi M ^a   Liuzzo, Giovanna ^a   Crea, Filippo ^a   Ghirlanda, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Inflammation; Monocytes; Pioglitazone

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METFORMIN; PIOGLITAZONE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG RESPONSE; HUMAN; LEUKOCYTE ACTIVATION; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPOLYSACCHARIDES; METFORMIN; MONOCYTES; THIAZOLIDINEDIONES;

EID: 59449086389     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-008-0058-3     Document Type: Article

References (10)

1. WB Kannel DL McGee 1979 Diabetes and cardiovascular disease. The Framingham study JAMA 241 2035 2038
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 229-234
3. Davies MJ (1989) The pathological basis of angina pectoris. Cardiovass Drugs Ther Suppl 1:249-255
4. PR Moreno AM Murcia IF Palcios 2000 Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus Circulation 102 2180 2184
5. DJ Freeman JJ Norrie MJ Caslake 2002 C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study Diabetes 51 1596 1600
6. P Mohanty A Aljada H Ghanim 2004 Evidence for a potent antiinflammatory effect of rosiglitazone J Clin Endocrinol Metab 89 6 2728 2735
7. N Marx J Froehlich L Siam 2003 Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease Arterioscler Thromb Vasc Biol 23 2 283 288
8. N Marx A Imhof J Froehlich 2003 Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease Circulation 107 15 1954 1957
9. R Ross 1999 Atherosclerosis-an inflammatory disease N Engl J Med 340 2 115 126
10. A Pfutzner N Marx G Lubben M Langerfeld D Walcher T Konrad T Forst 2005 Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study J Am Coll Cardiol 45 12 1925 1931